Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
Ultrasensitive Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine for Inhalation Solution
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented diagnosis of cystic fibrosis
- Age 18 years old or greater
- FEV1 percent predicted greater than 25%
- Ability to perform reproducible pulmonary function tests and produce sputum spontaneously
- Chronic bacterial colonization with Pseudomonas aeruginosa with 2 positive cultures in previous 2 years.
- Chronically stable pulmonary condition without evidence of acute pulmonary exacerbation within 14 days prior to screening
- Starting Cayston cycle as part of clinical care.
Exclusion Criteria:
- Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.
- Aztreonam allergy, bronchospasm or other contraindication to use of aztreonam.
- Signs and symptoms of acute pulmonary exacerbation at the time of enrollment or during study.
- Active infection and treatment for non-tuberculous mycobacteria.
- Concomitant use of systemic steroids.
- Use of inhaled antimicrobial agents with activity against Pseudomonas aeruginosa within 28 days prior to Visit 1.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
CF adults colonized with Pseudomonas aeruginosa
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gene biomarker panel
Time Frame: 1 month
|
Measurement of gene biomarkers by polymerase chain reaction before and after 1 month of Cayston therapy
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced expiratory volume in 1 second (FEV1)
Time Frame: 1 month
|
Change in pulmonary function (FEV1) after one month of Cayston therapy
|
1 month
|
|
Sputum Bacterial Density
Time Frame: 1 month
|
Change in sputum bacterial density after one month of Cayston
|
1 month
|
|
C-reactive protein
Time Frame: 1 month
|
Change in C-reactive protein after one month of Cayston
|
1 month
|
|
Interleukin 8
Time Frame: 1 month
|
Change in serum and sputum interleukin 8 concentrations after one month of Cayston
|
1 month
|
|
Patient reported symptom scores
Time Frame: 1 month
|
Change in patient reported symptoms after one month of Cayston
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IN-US-205-0171
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.